CM
VRTX icon

Churchill Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Churchill Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$9.79M Sell
21,996
-4,392
-17% -$2.02M 0.11% 75
2025
Q1 		$12.8M Sell
26,388
-19,069
-42% -$8.89M 0.16% 51
2024
Q4 		$18.3M Buy
45,457
+102
+0.2% +$47.3K 0.2% 35
2024
Q3 		$21.1M Sell
45,355
-501
-1% -$241K 0.24% 36
2024
Q2 		$21.5M Sell
45,856
-320
-0.7% -$139K 0.25% 34
2024
Q1 		$19.3M Sell
46,176
-368
-0.8% -$156K 0.24% 38
2023
Q4 		$18.9M Sell
46,544
-2,317
-5% -$856K 0.29% 30
2023
Q3 		$17M Sell
48,861
-1,540
-3% -$539K 0.29% 33
2023
Q2 		$17.7M Sell
50,401
-2,557
-5% -$862K 0.3% 32
2023
Q1 		$16.7M Sell
52,958
-2,216
-4% -$665K 0.34% 30
2022
Q4 		$15.9M Buy
55,174
+47,196
+592% +$14.4M 0.39% 30
2022
Q3 		$2.31M Buy
7,978
+43
+0.5% +$12.4K 0.06% 104
2022
Q2 		$2.24M Buy
7,935
+42
+0.5% +$11.2K 0.06% 109
2022
Q1 		$2.06M Buy
7,893
+345
+5% +$81.9K 0.04% 117
2021
Q4 		$1.66M Buy
+7,548
New +$1.47M 0.02% 137
2020
Q4 		– Sell
-9,905
Closed -$2.69M – 151
2020
Q3 		$2.69M Buy
9,905
+4,890
+98% +$1.35M 0.07% 106
2020
Q2 		$1.46M Buy
+5,015
New +$1.36M 0.05% 94
2020
Q1 		– Sell
-104,350
Closed -$22.8M – 131
2019
Q4 		$22.8M Buy
+104,350
New +$21.1M 0.43% 23
2018
Q4 		– Sell
-158,165
Closed -$30.5M – 148
2018
Q3 		$30.5M Buy
+158,165
New +$28.2M 0.66% 20

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Churchill Management's VRTX Position: Q2 2025 in Review

Churchill Management reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2025, selling an estimated $2.02M and leaving 21,996 shares worth $9.79M. The position accounts for 0.11% of the portfolio, ranked #75.

Churchill Management first reported a position in VRTX in Q3 2018 and has held it in 19 quarters since. The position peaked at $30.5M in Q3 2018. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Churchill Management held 21,996 shares of Vertex Pharmaceuticals worth $9.79M as of Q2 2025.
  • Churchill Management sold 4,392 Vertex Pharmaceuticals shares in Q2 2025, an estimated $2.02M.
  • Vertex Pharmaceuticals made up 0.11% of Churchill Management's portfolio in Q2 2025, its #75 holding.
  • Churchill Management first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 19 quarters since.
  • Churchill Management's Vertex Pharmaceuticals position peaked at $30.5M in Q3 2018.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Churchill Management's 13F filing for Q2 2025, filed 18 Jul 2025.